Showing 1241-1250 of 9359 results for "".
- Dupixent Significantly Improves Severe AD in Childrenhttps://practicaldermatology.com/news/dupixent-significantly-improves-severe-ad-in-children/2460338/Dupixent showed significant improvement in severe atopic dermatitis (AD) for children aged 6 to 11 Years, according to a Phase 3 study. In the trial, Dupixent combined with standard-of-care topical corticosteroids (TCS) significantly improved disease signs, symptoms and health-related quality of l…
- Dermira's Investigational AD Drug Performs Well in Phase 2b Trial, Shares Skyrockethttps://practicaldermatology.com/news/ready-for-phase-3-dermiras-investigational-ad-drug-performs-well-in-phase-2b-trial/2459969/All three doses of Dermira, Inc.’s lebrikizumab showed greater improvements in the Eczema Area and Severity Index in a new Phase 2b dose-ranging study of adults with moderate-to-severe atopic dermatitis, and shares of Dermira, Inc. skyrocketed in premarket trading after the company announced these …
- Nielsen BioSciences, Maruho Co. Ltd. Enter License Agreement for the Treatment of Common Wartshttps://practicaldermatology.com/news/nielsen-biosciences-maruho-co-ltd-enter-license-agreement-for-the-treatment-of-common-warts/2461719/Nielsen BioSciences, Inc. has entered into a license agreement with Maruho Co., Ltd. granting Maruho exclusive rights to market Candin in Japan for the treatment of Verruca vulgaris. Candin is an approved diagnostic skin test and currently not approved by the U,S. Food and Drug Administration (FD…
- Midmark Gives Back: Trade-in Program Results in Nearly 1,000 Exam Tables Donated to World Visionhttps://practicaldermatology.com/news/midmark-gives-back-trade-in-program-results-in-nearly-1000-exam-tables-donated-to-world-vision/2461347/Midmark Corp.'s 2021 trade-in program collected 1,000 eligible exam tables. The tables were donated primarily to World Vision, where they are refurbished and delivered to clinics that provide health care to children and families in remote areas of developing countries. The donation, valued at appro…
- Alastin to be Acquired by Galdermahttps://practicaldermatology.com/news/alastin-to-be-acquired-by-galderma/2460997/Galderma is set to acquire Alastin Skincare®, Inc. The world’s largest independent dermatology company has signed a definitive agreement to acquire the specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispensed skincare products. Financial terms of the…
- Verrica Enters Agreement with Lytix for Oncolytic Peptide for Dermatologyhttps://practicaldermatology.com/news/verrica-enters-agreement-with-lytix-for-oncolytic-peptide-for-dermatology/2460498/Verrica Pharmaceuticals Inc. has entered into an exclusive worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica intends to focus initially on basal cell and squamous cell carcinomas as the lead indications for develo…
- George W. Mahaffey Named CEO of Mindera Corporationhttps://practicaldermatology.com/news/george-w-mahaffey-named-ceo-of-mindera-corporation/2460480/George W. Mahaffey is the new President and Chief Executive Officer of Mindera Corporation. He will also serve as a Director of the Company. Mindera has developed a novel platform to extract thousands of biomarkers from an individual patient via a dermal biomarker patch. Captured RNA is then sent …
- LEO Pharma to Acquire Global Dermatology Portfolio from Astellashttps://practicaldermatology.com/news/leo-pharma-to-acquire-global-dermatology-portfolio-from-astellas/2458818/LEO Pharma A/S and Japanese pharmaceutical company Astellas Pharma Inc. have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for € 675 million. Under the terms of the agreement, the assets and associated responsibilities rel…
- Oral IL-23 Receptor Antagonist Makes Waves in Tokyohttps://practicaldermatology.com/news/oral-il-23-receptor-antagonist-makes-waves-in-tokyo/2461716/Protagonist Therapeutics and Janssen Biotech, Inc.'s oral IL-23 receptor antagonist, JNJ-2113, performed well in Phase 1 and Pre-clinical Studies. JNJ-2113 is a macrocyclic peptide that binds to the IL-23 receptor with single digit picomolar affinity and demonstrated potent, selective inhibition o…
- AAD Announces New Officers and Board Membershttps://practicaldermatology.com/news/aad-announces-new-officers-and-board-members/2458608/The American Academy of Dermatology (AAD) announced the results of its annual election. These new officers and board members also will hold the same positions for the American Academy of Dermatology Association. Suzanne Olbricht, MD, FAAD will take the office of Academy president-elect. Dr. Olbric…